Baillie Gifford Amends Sana Bio Stake; Passive Investment Noted
Ticker: SANA · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1770121
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**Baillie Gifford updated its passive stake in Sana Bio; watch for changes in their conviction.**
AI Summary
Baillie Gifford & Co, a prominent investment management firm, filed an amended SC 13G/A on January 26, 2024, indicating a change in their ownership of Sana Biotechnology, Inc. common stock as of December 29, 2023. This filing, an amendment to their previous disclosures, signals that Baillie Gifford & Co continues to hold a significant, though potentially adjusted, passive stake in Sana Biotechnology. For investors, this matters because large institutional holdings like Baillie Gifford's can provide a vote of confidence in the company's long-term prospects, but any significant reduction could signal concerns.
Why It Matters
This filing shows a major institutional investor's updated position in Sana Biotechnology, which can influence investor sentiment and potentially the stock's stability.
Risk Assessment
Risk Level: low — This is a routine amendment filing by a passive institutional investor, indicating no immediate high-risk events.
Analyst Insight
Investors should monitor future SC 13G/A filings from Baillie Gifford & Co to track any significant changes in their ownership percentage of Sana Biotechnology, as this could signal a shift in their investment thesis.
Key Players & Entities
- Baillie Gifford & Co (company) — the reporting person and investment management firm
- Sana Biotechnology, Inc. (company) — the subject company whose securities are being reported
- December 29, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G/A
- 799566104 (number) — the CUSIP number for Sana Biotechnology's Common Stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G (Amendment No.2)' sections.
Who is the reporting person in this filing?
The reporting person is BAILLIE GIFFORD & CO, as indicated under the 'FILED BY' section and 'Names of Reporting Persons' on the cover page.
What is the subject company of this filing?
The subject company is Sana Biotechnology, Inc., as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Sana Biotechnology, Inc.' and 'Name of Issuer' on the cover page.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 29, 2023, as specified in the 'Date of Event Which Requires Filing of this Statement' section.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the '[X] Rule 13d-1(b)' checkbox on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding Sana Biotechnology, Inc. (SANA).